ADA/EASD recommend considering combination injectables therapy of basal insulin/GLP-1 RA (Such as SOLIQUA®) as valuable treatment option to provide adequate efficacy for achieving and maintaining glycemic goals.


American Diabetes Association. Diabetes Care 2023;46(Suppl. 1):S140–S157 | https://doi.org/10.2337/dc23-S009
MAT-BH-2300161/v1/March 2023